HTF Market Intelligence released a new research report of 374 pages on title Atopic Dermatitis – Pipeline Review, H1 2017 with detailed analysis, forecast and strategies. The study covers key regions that includes North America, Europe and Asia-Pacific, South America, Middle East and Africa and important players such as AbbVie Inc 41
Request a sample report @ https://www.htfmarketreport.com/sample-report/291960-atopic-dermatitis-pipeline-review
Atopic Dermatitis – Pipeline Review, H1 2017
latest Pharmaceutical and Healthcare disease pipeline guide Atopic Dermatitis – Pipeline Review, H1 2017, provides an overview of the Atopic Dermatitis (Dermatology) pipeline landscape.
Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender.
Pharmaceutical and Healthcare latest pipeline guide Atopic Dermatitis – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Atopic Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Atopic Dermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 4, 40, 21, 1, 44, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 2 and 2 molecules, respectively.
Atopic Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Atopic Dermatitis (Dermatology).
– The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Atopic Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Atopic Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Atopic Dermatitis (Dermatology)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Atopic Dermatitis (Dermatology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Atopic Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Make an enquiry before buying this Report @ https://www.htfmarketreport.com/enquiry-before-buy/291960-atopic-dermatitis-pipeline-review
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 10
Report Coverage 11
Atopic Dermatitis – Overview 12
Atopic Dermatitis – Therapeutics Development 13
Pipeline Overview 13
Pipeline by Companies 14
Pipeline by Universities/Institutes 20
Products under Development by Companies 21
Products under Development by Universities/Institutes 28
Atopic Dermatitis – Therapeutics Assessment 29
Assessment by Target 29
Assessment by Mechanism of Action 33
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Atopic Dermatitis – Companies Involved in Therapeutics Development 41
AbbVie Inc 41
Accolade Pharmaceuticals LLC 41
Albireo Pharma Inc 42
Almirall SA 42
Amgen Inc 43
Amorepacific Corp 43
AnaptysBio Inc 44
AnGes MG Inc 44
Antibiotx ApS 45
Avexxin AS 45
Blueberry Therapeutics Ltd 46
Brickell Biotech Inc 46
Celgene Corp 47
Cell Medica Ltd 47
Cellceutix Corp 48
ChemoCentryx Inc 48
ChironWells GmbH 49
Chugai Pharmaceutical Co Ltd 49
Clevexel Pharma SA 50
Curapel Ltd 50
Cutanea Life Sciences Inc 51
Dermala Inc 51
Dr. August Wolff GmbH & Co KG Arzneimittle 52
Eli Lilly and Company 52
Exicure Inc 53
F. Hoffmann-La Roche Ltd 53
Foamix Pharmaceuticals Ltd 54
Fountain Biopharma Inc 54
Galapagos NV 55
Galectin Therapeutics Inc 55
GlaxoSmithKline Plc 56
Glenmark Pharmaceuticals Ltd 56
Grupo Ferrer Internacional SA 57
GTx Inc 57
Han Wha Pharma Co Ltd 58
HanAll Biopharma Co Ltd 58
Heptares Therapeutics Ltd 59
Herantis Pharma Plc 59
iCo Therapeutics Inc. 60
Immune Pharmaceuticals Inc 60
Incyte Corp 61
Inflamalps SA 61
Japan Tobacco Inc 62
Kang Stem Biotech Co Ltd 62
KPI Therapeutics Inc 63
LEO Pharma A/S 63
Madam Therapeutics BV 64
MedImmune LLC 64
NeoPharm Co Ltd 65
Novan Inc 65
Novartis AG 66
Orbis Biosciences Inc 66
Otsuka Holdings Co Ltd 67
Oxagen Ltd 67
Pfizer Inc 68
Pharis Biotec GmbH 68
Pharmedartis GmbH 69
Provectus Biopharmaceuticals Inc 69
Qurient Co Ltd 70
Realm Therapeutics Plc 70
Regeneron Pharmaceuticals Inc 71
Roivant Sciences Ltd 71
Signum Biosciences Inc 72
Signum Dermalogix Inc 72
Spherium Biomed SL 73
sterna biologicals Gmbh & Co KG 73
Sun Pharma Advanced Research Company Ltd 74
SWITCH Biotech LLC 74
Thesan Pharmaceuticals Inc 75
Torrent Pharmaceuticals Ltd 75
Trevi Therapeutics Inc 76
Valeant Pharmaceuticals International Inc 76
Vicore Pharma AB 77
Vitae Pharmaceuticals Inc 77
VivaCell Biotechnology Espana SL 78
Xencor Inc 78
Zhejiang I-Biological Technology Co Ltd 79
Atopic Dermatitis – Drug Profiles 80
A-3914 – Drug Profile 80
A-5425 – Drug Profile 81
AKP-11 – Drug Profile 82
Allergen for House Dust Mite Induced Atopic Dermatitis – Drug Profile 84
ALX-101 – Drug Profile 85
AMG-0101 – Drug Profile 86
Anatabine – Drug Profile 88
ANB-020 – Drug Profile 91
Antisense Oligonucleotide to Antagonize IL-4RA for Atopic Dermatitis – Drug Profile 93
apremilast – Drug Profile 94
Aptamers to Inhibit Galectin-3 for Atopic Dermatitis – Drug Profile 106
ARN-077 – Drug Profile 107
AVX-001 – Drug Profile 108
AZT-01 – Drug Profile 110
B-244 – Drug Profile 111
baricitinib – Drug Profile 113
BB-2702 – Drug Profile 123
BBI-2000 – Drug Profile 124
BBI-5000 – Drug Profile 125
bertilimumab – Drug Profile 126
betamethasone valerate – Drug Profile 130
Biologic for Atopic Dermatitis – Drug Profile 131
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/291960-atopic-dermatitis-pipeline-review
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=291960
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218